EYEN Eyenovia Inc

Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10

Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10

Company to host an investor conference call and webcast at 4:30pm ET on that day

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will release financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020, after market close. Following the release, Eyenovia’s Chief Executive Officer and Chief Medical Officer Dr. Sean Ianchulev, Chief Financial Officer John Gandolfo, and Vice President of Commercial Michael Rowe, will host a conference call to review the financial and operating results.

The conference call is scheduled to begin at 4:30 pm ET on Tuesday, November 10, 2020. Participants should dial 877-407-9039 (domestic) or 201-689-8470 (international) with the conference code 13713084. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at .

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, pediatric myopia progression and mydriasis. For more Information, please visit .

Eyenovia Investor Contacts:

John Gandolfo



(917) 289-1117

Eric Ribner

LifeSci Advisors, LLC



(646) 751-4363

Eyenovia Media Contact:

Diana Soltesz

Pazanga Health Communications

(818) 618-5634

EN
05/11/2020

Underlying

EYENEyenovia Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eyenovia Inc

 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYP...

Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy Increases total holdings to 1,535,772 HYPE Company to host investor webinar on Tuesday, July 29th at 2:00pm ET LAGUNA HILLS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced that it has acquired an additional 108,594 HYPE tokens, expanding its total holdings to 1,535,772 HYPE purchased at an average price of $36.14 per token. This latest purchase is in preparation of deploying HYPE into Kinetiq’s iHYPE (“Institutional HYPE”) po...

July 28, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evol...

Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evolution from Eyenovia and the Future of On-Chain Finance on July 29, 2025 LAGUNA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced that it will host a special corporate update event on Tuesday, July 29, 2025 at 2:00 PM ET with CIO Hyunsu Jung and CEO Michael Rowe, to discuss the Company's bold transformation from a digital ophthalmic tech company into the first publicly-listed U.S. firm focused on building a strategic treasury around HYP...

July 17, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings

Hyperion DeFi Adds $5 Million in HYPE to its Treasury Holdings Increases total holdings to 1,427,178 HYPE LAGUNA HILLS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 120,726 HYPE tokens, expanding its total holdings to 1,427,178 HYPE purchased at an average price of $35.38 per token. “This latest acquisition...

July 14, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion De...

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc. Name change reflects company’s leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol “HYPD” effective July 3rd Also announces official launch of the Kinetiq x Hyperion validator LAGUNA HILLS, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, th...

July 2, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparat...

Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement Increases total holdings to 1,306,452 HYPE LAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 265,872 HYPE tokens, expanding its total holdings to 1,306,452 HYPE purchased at an average price of $34.83 pe...

June 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch